Last Updated2026-06-02

Market View

₹241.19(▲1.05%)

Reporting PeriodQ4 FY26

MARKSANSMarksans Pharma Limited Forensic Risk Analysis

Name: Marksans Pharma Limited Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market Cap₹7,755 Cr

Primary DriverEarnings Quality

Flagium AI Risk Score

10 / 100

-5 QoQ

Improving

Sentinel Insight

Financial profile remains stable for now. Pressure is receding in profitability and earnings quality. This indicates that forensic pressure is currently receding. Risk levels are improving.

25.3th %ile (Sector)Accel: +0 Qtrs

Updated2026-06-02

Market View

₹241.19▲1.05%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Earnings Quality

+7.9 pts

Stability Adjustment

+2.0 pts

Final Composite Risk10 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 5 → 10 over 13 quarters.

Expected Direction

🟢 Improving

Primary Deterioration Drivers

Inventory Stress
Industrial Margin Stress
Operating Leverage Stress

What to Watch Next Quarter

Operating cash flow
Operating profit margins
Debt growth

Active Risk Objects (5)

CriticalHigh

Cash Conversion Deficit

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight6/15

MomentumPersistent

Last SignalFY2026

MARKSANS: OCF below Net Profit in 2/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Profit Collapse

📊 Earnings QualityQuarterlyActive for 1 Qtrs

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ4 FY2025

MARKSANS: Net Profit collapsed by 88.3% from FY2024 Q4 to FY2025 Q4.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Industrial Margin Stress

📉 Trend DeteriorationAnnualActive for 6 Years

More Detail

Impact Weight12/15

MomentumPersistent

Last SignalQ4 FY2026

MARKSANS: Raw material costs consumed an additional 3.8% of revenue YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Operating Leverage Stress

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ3 FY2026

Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Inventory Stress

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight15/15

MomentumPersistent

Last SignalQ2 FY2026

Inventory growth (26.0%) significantly outpaced revenue growth (13.6%).

"Slight build-up in inventory detected. Monitor for slowing sales momentum."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	3.75	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+56.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹241.19(+1.05%)

1M Divergence+28.37%

1 Week-5.34%

1 Month+30.63%

6 Months+28.43%

1 Year-5.14%

2 Year+63.26%

3 Year+194.75%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in earnings quality remain well-maintained against forensic benchmarks. Systematic scans of operational margins and profitability metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

MARKSANS • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.98%

Trend QualityStrong

Phase Progression

Phase Progression Score100%

Readiness LabelHigh (Phase Transition Imminent)

Probability of Advancing98%

CoinTree Momentum

Composite Z-Score+1.2871σ

Strong positive momentum leadership

Universe Rank#174 of 2716

Top 6.41% in momentum strength

Timeframe Sparklines

1W-5.3%

1M+30.6%

6M+28.4%

Weinstein Indicators

150 DMA₹184.23

200 DMA₹182.1

150 DMA Slope+3.3279%Rising

Relative Strength+33.92%Leading

Relative Turnover (RTR)3.0920

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
MARKSANSMarksans Pharma Limited	10	25th	-5	5	+0	Earnings QualityStable
AARTIDRUGSAarti Drugs Limited	19	51th	-5	11	+0	Competitive PositionStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch
AARTIPHARMAarti Pharmalabs Limited	35	81th	0	18	+0	Earnings QualityWatch